Unfortunately, the NCCN guidelines for the treatment of non-small-cell lung cancer from January 2025 do not indicate the place of drugs using the blockade of the TIGIT, TIM-3, or LAG-3 checkpoints [67]. The gene discussed is HAVCR2; the disease is non-small cell lung carcinoma.